{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:31:29Z","timestamp":1791178289853,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1740,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p>The population pharmacokinetics of infliximab were characterized in patients with active ankylosing spondylitis (n =274). Serum infliximab concentration data, from a 2\u2010year period, were analyzed using NONMEM. A 2\u2010compartment linear pharmacokinetic model was chosen to describe the pharmacokinetic characteristics of infliximab in serum. Population estimates (typical value \u00b1 standard error) were obtained from the final covariate model: clearance (CL: 0.273 \u00b1 0.007 L\/day), volume of distribution in the central compartment (V<jats:sub>1<\/jats:sub>: 3.06 \u00b1 0.057 L), intercompartment clearance (Q: 1.72 \u00b1 0.48 L\/day), and volume of distribution in the peripheral compartment (V<jats:sub>2<\/jats:sub>:2.94 \u00b1 0.17 L). Interindividual variability for CL and V<jats:sub>1<\/jats:sub> was 34.1% and 17.5%, respectively. White blood cell count at baseline and the antibody\u2010to\u2010infliximab status were significant covariates to CL; body surface area and sex were significant covariates to V<jats:sub>1<\/jats:sub>. The CL for patients with a positive antibody\u2010to\u2010infliximab status was estimated to be 41.9% to 76.7% higher than for the remaining patients. Other covariates (baseline disease activity and the concomitant medication use of prednisolone, omeprazole, nonsteroidal anti\u2010inflammatory drugs, or analgesics) did not affect infliximab pharmacokinetics. The development of antibodies to infliximab was associated with accelerated infliximab clearance and may represent a potential underlying mechanism for an inadequate response, or loss of response, to infliximab treatment.<\/jats:p>","DOI":"10.1177\/0091270008316886","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T01:54:50Z","timestamp":1207792490000},"page":"681-695","source":"Crossref","is-referenced-by-count":99,"title":["Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis"],"prefix":"10.1002","volume":"48","author":[{"given":"Zhenhua","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adedigbo","family":"Fasanmade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.7.1097"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.5.429"},{"issue":"28","key":"e_1_2_5_4_2","first-page":"S16","article-title":"Mortality, course of disease and prognosis of patients with ankylosing spondylitis","volume":"20","author":"Braun J","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.52.3.174"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380407"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.6.404"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_5_9_2","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6973.170"},{"key":"e_1_2_5_13_2","volume-title":"Guidance for Industry: Population Pharmacokinetics","year":"1999"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003254802"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277075"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004272731"},{"key":"e_1_2_5_17_2","first-page":"301","volume-title":"Introduction to Linear Regression Analysis","author":"Montgomery DC","year":"1982"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00098-4"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80164-9"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298188"},{"key":"e_1_2_5_21_2","first-page":"841","article-title":"Chimeric anti\u2010tumor necrosis factor\u2010\u03b1 monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh A","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_5_22_2","first-page":"A614","article-title":"Comparative pharmacokinetics of single and multiple\u2010dose infliximab in Crohn's disease patients","volume":"122","author":"Boyle A","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298360"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006294278"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007306958"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.813"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270008316886","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270008316886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:13:26Z","timestamp":1697109206000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270008316886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1177\/0091270008316886"],"URL":"https:\/\/doi.org\/10.1177\/0091270008316886","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}